2-methoxyestradiol
information and resources from the National Cancer Institute
NCI Thesaurus | 2-methoxyestradiol
An orally bioavailable estradiol metabolite with potential antineoplastic activity. 2-Methoxyestradiol inhibits angiogenesis by reducing endothelial cell proliferation and inducing endothelial cell apoptosis. This agent also inhibits tumor cell growth by binding to tubulin, resulting in antimitotic activity, and by inducing caspase activation, resulting in cell cycle arrest in the G2 phase, DNA fragmentation, and apoptosis.NCI Thesaurus | 2-methoxyestradiol
An orally bioavailable estradiol metabolite with potential antineoplastic activity. 2-Methoxyestradiol inhibits angiogenesis by reducing endothelial cell proliferation and inducing endothelial cell apoptosis. This agent also inhibits tumor cell growth by binding to tubulin, resulting in antimitotic activity, and by inducing caspase activation, resulting in cell cycle arrest in the G2 phase, DNA fragmentation, and apoptosis.
|
|
|
|
news articles
PR Pharmaceuticals issued US patent covering 2-methoxyestradiol ... Mar 21, 2006
News-Medical.net, PR Pharmaceuticals has announced the issuance of US Patent No. 6,998,395 covering 2-methoxyestradiol (2ME) for the treatment of diabetes. ...
EntreMed to Present at the BioCentury Future Leaders in the ... Mar 27, 2006
Yahoo! News (press release) Panzem® (2-methoxyestradiol or 2ME2), the Company's lead drug candidate, is currently in Phase 2 clinical trials for cancer, as well as in preclinical ...
EntreMed gets new patent for novel compound Mar 17, 2006
Pharmaceutical Business Review Cancer and inflammatory disease specialist EntreMed has been granted a US patent to cover its lead clinical-stage compound, 2-methoxyestradiol, in a broad ...
New Patent Issued to the University of Pittsburgh for 2 ... Mar 16, 2006
PR Newswire (press release), ...(PRP), announced today the issuance of US Patent No. 6,998,395 covering 2-methoxyestradiol (2ME) for the treatment of diabetes. ...
EntreMed Presents Preclinical Data Supporting 2ME2's DMARD ... Mar 22, 2006
Yahoo! News (press release) ...the treatment of cancer and inflammatory diseases today announced the presentation of preclinical data for its lead compound, 2- methoxyestradiol (2ME2), in ...
PRP Announces Initiation of a Phase I Study of a New Potential ... Mar 27, 2006
Yahoo! News (press release) ...(PRP) announced today that healthy volunteers were dosed with PulmoLAR(TM) (2-methoxyestradiol - 2ME) in a Phase I clinical study. ...
New 2ME2 Patent Strengthens EntreMed's Position in Cancer and Non ... Mar 16, 2006
PR Newswire (press release), 7,012,070 covering methods of treatment for a broad range of indications with its lead clinical-stage compound, 2-methoxyestradiol (2ME2). ...
EntreMed announces new US Patent - "Estrogenic Compounds as Anti ... Mar 17, 2006
News-Medical.net, 7,012,070 covering methods of treatment for a broad range of indications with its lead clinical-stage compound, 2-methoxyestradiol (2ME2). ...
EntreMed Gets License for Panzem Patent Mar 16, 2006
MSN Money The patent covers the use of 2-methoxyestradiol, the active ingredient in Panzem, for a wide range of diseases independent of mechanism for the treatment of ...
PR Pharmaceuticals Files IND for Pulmonary Hypertension Dec 19, 2005
Yahoo! News (press release) New Drug (IND) application with the US Food and Drug Administration (FDA) for the Company's first clinical product, PulmoLAR(TM) (2-methoxyestradiol) for the ...
EntreMed Receives Composition of Matter Patent Claims for 2ME2 Dec 7, 2005
PR Newswire (press release), ...a notice of allowance from the US Patent & Trademark Office (PTO) of a patent application claiming composition of matter for purified 2-methoxyestradiol (2ME2 ...
EntreMed and Affymax Present Preclinical Data for Novel ... Dec 13, 2005
PR Newswire (press release), Panzem(R) (2-methoxyestradiol or 2ME2), the Company's lead drug candidate, is currently in clinical trials for cancer, as well as in preclinical development ...
EntreMed Receives New Panzem Patent Dec 7, 2005
MSN Money The new patent covers a highly purified version of 2-methoxyestradiol, the active ingredient in Panzem NCD, and extends patent protection on the compound until ...
|
|
